Search research articles
Contact Us
Filters
Showing results (81-90 of 135) with videos related to
Page
of 14
Sort By:
Blood
|
January 15, 2025
Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
Pallavi Galera, Deepika Dilip, Andriy Derkach, et al.
Blood Cancer Journal
|
March 27, 2026
Dietary patterns among individuals with plasma cell disorders- opportunities for targeted interventions
Kadiatou Traore, Francesca Castro, Andriy Derkach, et al.
Haematologica
|
October 4, 2024
Evaluating serum free light chain ratio as a biomarker in multiple myeloma
Theresia Akhlaghi, Kylee Maclachlan, Neha Korde, et al.
Blood Advances
|
December 6, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure
Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, et al.
Blood Cancer Journal
|
October 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2021
Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
Raajit K Rampal, Maria Pinzon-Ortiz, Amritha Varshini Hanasoge Somasundara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2020
Chemotherapy and COVID-19 Outcomes in Patients With Cancer
Justin Jee, Michael B Foote, Melissa Lumish, et al.
Blood Advances
|
March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
Cancer Investigation
|
October 28, 2021
Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room
Sandy Simcha Nath, Nandini Umesh Yadav, Andriy Derkach, et al.
Blood Cancer Journal
|
July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 135) with videos related to
Sort By:
Page
of 14
Blood
|
January 15, 2025
Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
Pallavi Galera, Deepika Dilip, Andriy Derkach, et al.
Blood Cancer Journal
|
March 27, 2026
Dietary patterns among individuals with plasma cell disorders- opportunities for targeted interventions
Kadiatou Traore, Francesca Castro, Andriy Derkach, et al.
Haematologica
|
October 4, 2024
Evaluating serum free light chain ratio as a biomarker in multiple myeloma
Theresia Akhlaghi, Kylee Maclachlan, Neha Korde, et al.
Blood Advances
|
December 6, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure
Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, et al.
Blood Cancer Journal
|
October 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2021
Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
Raajit K Rampal, Maria Pinzon-Ortiz, Amritha Varshini Hanasoge Somasundara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2020
Chemotherapy and COVID-19 Outcomes in Patients With Cancer
Justin Jee, Michael B Foote, Melissa Lumish, et al.
Blood Advances
|
March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
Cancer Investigation
|
October 28, 2021
Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room
Sandy Simcha Nath, Nandini Umesh Yadav, Andriy Derkach, et al.
Blood Cancer Journal
|
July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Page
of 14